Guerbet invests in the Truffle Capital fund dedicated to medical devices and biotechnologies
Guerbet today announced that it has signed an equity acquisition of fifteen million Euros in the BioMedTech fund (FPCI) managed by Truffle Capital
Truffle Capital specializes in investing in start-ups developing technologies and breakthrough products in the life sciences sector.
The BioMedTech fund which targets 200 million Euros is dedicated to investments in a dozen essentially French start-ups. They are mostly MedTechs but some are also BioTechs working in the fields of minimally invasive interventional medicine and biotechnology products offering breakthrough improvements, particularly in cardiovascular, osteoarticular, and infectious diseases, or neurology, dermatology, and oncology.
“This investment completes Guerbet’s innovation strategy. We want to actively contribute to the development of new diagnostic or therapeutic solutions that are very innovative for the health of patients, particularly those based on minimally invasive, ambulatory or image-guided procedures. We appreciate Truffle Capital’s entrepreneurial approach and their focus on radical innovations in medicine,” said Yves L'Epine, CEO of Guerbet.